S
Steven E Waggoner
Researcher at University of Chicago
Publications - 82
Citations - 4523
Steven E Waggoner is an academic researcher from University of Chicago. The author has contributed to research in topics: Radiation therapy & Endometrial cancer. The author has an hindex of 33, co-authored 75 publications receiving 4058 citations. Previous affiliations of Steven E Waggoner include Case Western Reserve University & Georgetown University Medical Center.
Papers
More filters
Journal ArticleDOI
Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies.
Arno J. Mundt,Anthony E Lujan,Jacob Rotmensch,Steven E Waggoner,S. Diane Yamada,Gini F. Fleming,John C. Roeske +6 more
TL;DR: Treatment was well tolerated and associated with less acute gastrointestinal sequelae than conventional WPRT, and IMRT planning resulted in excellent PTV coverage, with considerable sparing of the surrounding normal tissues.
Journal ArticleDOI
Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies
TL;DR: The results suggest that IM-WPRT is an effective means of reducing the volume of small bowel irradiated in women with gynecologic malignancies receiving WPRT, and potentially offers a method for reducing small bowel complications in patients with gy pelvic cancer.
Journal ArticleDOI
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Krishnansu S. Tewari,Michael W. Sill,Richard T. Penson,Helen Huang,Lois M. Ramondetta,Lisa M. Landrum,Ana Oaknin,Thomas J. Reid,Thomas J. Reid,Mario M. Leitao,Helen Michael,Philip J. DiSaia,Larry J. Copeland,William T. Creasman,Frederick B. Stehman,Mark F. Brady,Robert A. Burger,J. Tate Thigpen,Michael J. Birrer,Steven E Waggoner,David H. Moore,Katherine Y. Look,Wui Jin Koh,Bradley J. Monk +23 more
TL;DR: In this article, the authors report the prespecified final analysis of the primary objectives, OS and adverse events, assessed at the second interim and final analysis by the masked Data and Safety Monitoring Board.
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Krishnansu S. Tewari,Michael W. Sill,Richard T. Penson,Helen Huang,Lois M. Ramondetta,Lisa M. Landrum,Ana Oaknin,Thomas J. Reid,Thomas J. Reid,Mario M. Leitao,Helen Michael,Philip J. DiSaia,Larry J. Copeland,William T. Creasman,Frederick B. Stehman,Mark F. Brady,Robert A. Burger,J. Tate Thigpen,Michael J. Birrer,Steven E Waggoner,David H. Moore,Katherine Y. Look,Wui Jin Koh,Bradley J. Monk +23 more
TL;DR: The chemotherapy plus bevacizumab groups continued to show significant improvement in OS compared with the chemotherapy-alone groups, meeting the prespecified cutoff for final analysis.
Journal ArticleDOI
Identification of Tobacco- Specific Carcinogen in the Cervical Mucus of Smokers and Nonsmokers
TL;DR: The cervical mucus of cigarette smokers contains measurable amounts of the potent carcinogen NNK, which represents the first tobacco-specific carcinogen identified in this physiologic fluid of women who smoke cigarettes.